B Cells--Tumors clinical trials at UC Cancer

• Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

  open to eligible people ages 18 years and up

  First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 2 weeks.

  at UC Davis UCSF

Last updated: July 24, 2020